– USA, CA – Align Technology, Inc. (NASDAQ: ALGN) today announced the appointment of Mojdeh Poul and Kevin Conroy to its Board of Directors.
“I am pleased to welcome Mojdeh and Kevin to Align’s board of directors,” said CEO Joe Hogan. “Each brings extensive experience across the healthcare industry that complements the depth and breadth of Align’s board. Mojdeh has led global businesses and operations in large multinational organizations and has deep expertise in business strategy and transformation, as well as commercial excellence. Kevin has an exceptional track-record for growth and his technical and clinical expertise, combined with a focus on digitally innovative solutions, have delivered amazing customer experiences. Mojdeh and Kevin are both outstanding additions to our board and I am confident that their knowledge and insights will benefit Align as we continue to drive the evolution of digital orthodontics and restorative dentistry globally.”
About Mojdeh Poul
Mojdeh Poul was most recently EVP and group president of 3M Health Care where she was responsible for its global P&L, strategy, research & development, manufacturing, and commercial operations. During her tenure at 3M, Ms. Poul held leadership roles, including EVP of Safety & Graphics Business Group, president of 3M Canada, and president of two divisions within the 3M Health Care Business Group. Before 3M, Ms. Poul held several leadership roles of increasing responsibility with Medtronic and Boston Scientific, two leading global medical technology companies. Before this, Ms. Poul held engineering positions with General Electric Plastics. Ms. Poul currently serves as a director of iRhythm Technologies and Stanley Black and Decker.
Ms. Poul holds an M.B.A. degree from the University of North Carolina, Chapel Hill, and an M.Eng. and B.S. degree in Mechanical Engineering from the University of Louisville.
About Kevin Conroy
Kevin Conroy is President, CEO, and Chairman of the Board of Exact Sciences Corporation. He became CEO in 2009 and Chairman in 2014, transforming the organization into one of the world’s premier cancer diagnostics companies. Mr. Conroy led Exact Sciences through the development and commercialization of its noninvasive colorectal cancer screening test, Cologuard, which became the first medical device or diagnostic to receive simultaneous FDA approval and national Medicare coverage. Before Exact Sciences, Mr. Conroy served as CEO and president of Third Wave Technologies, held leadership positions at GE Healthcare, and practiced intellectual property law in private practice. Mr. Conroy formerly served as a director of Adaptive Biotechnologies Corporation, Epizyme, Inc., and SomaLogic, Inc.
Mr. Conroy holds a J.D. degree from the University of Michigan Law School and a B.S.E. degree in Electrical Engineering from Michigan State University.
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign System, the most advanced clear aligner system in the world, iTero intraoral scanners and services, and exocad CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 252 thousand doctor customers and is key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 26 years, Align has helped doctors treat 16.4 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners.
SOURCE: https://www.aligntech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.